AYUSH System and COVID-19 Pandemic


 

The novel coronavirus disease, commonly known as COVID-19, has posed an unprecedented challenge to health care systems across the world. The speed and size of its spread has rendered most health care models ineffective and policy makers are forced to frequently change strategies to contain the pandemic to accommodate daily realities. In the absence of any known vaccine and drug for COVID-19 in modern medicine, containment appears to be the only way forward. Accordingly, most countries follow the model of isolation and social distancing to contain the spread. For various reasons, this has not been very successful so far in Western Europe and the United States, as the number of affected individuals and mortality continue to rise rapidly. India is one of the few countries that took relatively early steps to implement isolation and social distancing. This was a much-needed and correct strategy, given the size and density of the population and the comparatively low income levels of the majority of people who make their living on a daily basis. The disease is still spreading. The first case was reported on 30 January 2020 and the number has been increasing ever since. This is a tough task facing Indian healthcare policymakers and professionals.

Challenges of the Indian healthcare system during the current pandemic

India's healthcare is already struggling with a number of issues including a heavy disease burden, lack of adequate health infrastructure and manpower. Compared to most high-income countries, India has a lot to catch up on in these areas. According to the latest data available on the World Bank's World Development Indicators (WDI) database, India has only 0.7 hospital beds per 1000 population, while the US has 2.9 and Italy has 3.4. Similarly, if we compare the health sector workforce, as of 2017, India had only 2.1 nurses per 1000 population, while Italy had 5.9 and the US had 8.5–5.1. India has about 50 million people suffering from diabetes and 54 million from cardiovascular diseases (CVD).2 India also has the highest number of people suffering from tuberculosis, which is about 2.8 million (ibid). The morbidity profile of the country as well as the lack of health care infrastructure and resources to meet the needs of normal times, makes COVID 19 a serious challenge for India. Therefore, India has to make optimal use of all available resources to deal with the current crisis. This applies to health infrastructure, human resources and medical equipment and immunity-boosting drugs and food supplements.

AYUSH as a Quickly Utilised Resource

A key resource that India has is its AYUSH sector, which comprises the traditional medical systems of Ayurveda, Siddha, Unani, Yoga and Sowa-Rigpa and the modern system of homeopathy. In crisis situations like the present one, this sector is a great asset to India as compared to countries in the West. Its infrastructure, human resources and even medicines and lifestyle prescriptions come in handy to the country in dealing with the pandemic. Table 1 presents the AYUSH healthcare infrastructure and human resources in India in detail. As of March 2020, India had 3,986 AYUSH hospitals and 27,199 registered AYUSH dispensaries. Ayurveda is the most popular system of traditional medicine (TM) in India with 3186 hospitals and 17,102 dispensaries. These endowed facilities, which are spread across the country, can be used for isolation and quarantine facilities under proper supervision, following what the current treatment protocol prescribes. The same is the case with human resources. There are about 1.4 million registered AYUSH doctors spread across India. A large number of these personnel, about 6 lakh, have done regular five-and-a-half-year graduation and many of them have also done three-year postgraduate course in formal AYUSH medical colleges and universities. According to the ministry's annual report for 2018-19, there are 401 Ayurveda, 11 Siddha and 53 Unani colleges affiliated to 59 universities in the country. Of these, 155 institutions offer postgraduate courses in Indian System of Medicine (ISM). According to the ministry's dashboard, the capacity of these institutions is 46,835 in undergraduate and 5,885 in postgraduate courses. Those who studied and trained in the modern curriculum of these systems in formal institutions can easily handle the general health protocols, especially where there is no allopathy medicine use, which, in any case, is not for COVID patients except if they are suffering from other diseases. or bronchial problems, which may increase during COVID-19. This is certainly better than leaving patients to take care of themselves at home. Indian systems of medicine like Ayurveda lay a lot of emphasis on immunity development. A large number of medicines in these systems are already marketed as food and nutritional supplements, especially in countries where the systems are not recognised as medical systems. They, like Chyavanaprash, are targeted at the body's immunity. These are products with fewer side effects, although they should be taken under the supervision of qualified health practitioners. They are ideal to take in case of infectious diseases that affect the immune system, as preventive medicine. There are 8,964 AYUSH manufacturing units that can supply adequately, if allowed to do so. The systems also lay emphasis on the diet (pathya) and lifestyle (jeevchariya) of the individual, as the effectiveness of medicines depends on that. All of these are part of preventive medicine and contribute to immunity development. Modern health experts also recommend healthy diet and anti-stress activities. Ayurveda and yoga seem to be a perfect combination for both.

One advantage of AYUSH systems is the accessibility of most products, especially in rural areas. Indian systems of medicine talk about the definite beneficial effects of Indian spices in boosting immunity. Many AYUSH immunomodulators use ingredients that can be found in most Indian households such as turmeric, basil, ginger, mustard oil, etc. Using these ingredients, households can prepare immunoboosters like kashayam for daily consumption. This will serve a dual purpose as people will not have to step out of their homes to prepare these, thus respecting the lockdown, as well as help build their immunity. It must be noted that these formulations are prescribed only as precautionary measures and not as a cure, until scientifically proven otherwise, so that all other preventive measures such as regular hand washing are not ignored. There is ample evidence that yoga helps in stress and anxiety management and can improve mental health. Just like homegrown Ayurvedic formulations, Yoga too has a household benefit if promoted through mass media. Using these measures the Indian population can prepare against the virus without any side effects at a very low cost. Perhaps, these preventive measures will reduce the chances of developing severe symptoms if infected with the new Corona virus. Although most COVID 19 cases are asymptomatic or show only mild symptoms, there are still chances that a large portion of the population will eventually develop severe symptoms after getting infected. If and when this happens, it is absolutely necessary that the established AYUSH infrastructure and health care workers along with allopathic doctors and modern health care infrastructure are well prepared to take care of those patients. For this to happen, the government must start using AYUSH resources before community spread so that they are prepared for what is to come. It is important to build trust and confidence in the systems. It is also necessary to spread awareness through mass media, social media and print media. Also, the AYUSH Ministry should be very vigilant to eliminate any false claims arising during this time as they hamper the legitimacy of the system. Such false claims and fake cures will cause serious damage to the system.

Policy Initiatives and Interventions

The Ministry of AYUSH started its preparations even before the first case of COVID-19 was reported in India. While the first COVID 19 case in India was reported on January 30, 2020, already on January 29, 2020, the Ministry of AYUSH had issued an advisory for the corona virus. In the advisory, the ministry prescribed immunomodulatory Ayurvedic medicines as a preventive measure against the COVID-19 disease. The ministry also prescribed Unani medicines that may prove useful in the symptomatic management of corona virus infection. The advisory clearly mentions that it is for information only and should be adopted in consultation with a registered AYUSH physician. The ministry also clarified that they do not claim that these medicines work as a cure for COVID-19. These medicines are time-tested preventive measures that have been used against respiratory diseases. The advisory also mentions lifestyle related advice such as regular hand washing and consuming light and easily digestible food. Even the Ministry of Health and Family Welfare (MoHFW, India) has taken AYUSH systems and AYUSH practitioners into consideration in their advisory. In their press release dated March 18, MoHFW has issued guidelines for COVID 19 affected patients by public and private institutions and health practitioners. Both allopathic and AYUSH practitioners can inform the ministry about a potential COVID 19 affected patient. The Government of India issued a mandatory lockdown of 21 days across India on March 25, 2020 to curb the spread of the viral infection. To effectively manage the lockdown at the individual level, the Ministry of AYUSH acted swiftly and launched the Yoga at Home campaign. In this campaign, they released a daily yoga asana to combat stress and promote physical and mental well-being during the lockdown. On 28 March 2020, Prime Minister Shri Narendra Modi met representatives of the AYUSH sector to discuss the COVID-19 outbreak. The PM underscored the importance of fact-checking and refuting baseless claims of AYUSH having a cure for the disease. He said that scientists from AYUSH, Indian Council of Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR) and other research organisations should come together for evidence-based research. The Prime Minister urged AYUSH stakeholders to use the platform of telemedicine to reach out to the public and create sustained awareness. There is a need for an integrated approach that recognises the importance of both AYUSH and allopathic systems of medicine. Following that meeting, the Ministry of AYUSH launched a COVID19 Input Portal on its website. On this portal, any registered AYUSH practitioner can submit suggestions, concepts or proposals regarding the infection. The suggestions received so far from eminent Vaidyas across the country have been made public as an advisory by the Ministry of AYUSH. The advisory now needs to be disseminated and advertised through popular channels such as mass media and social media. The Home Secretary, Government of India, in his letter dated 2 April 2020 clarified that AYUSH hospitals, dispensaries, individual clinics, distribution of medicines, manufacturing units and medicine packaging units fall under exemption from lockdown and will continue to serve the people.

Way Forward

Even though the steps taken so far are welcome, there is still a long way to go to effectively use AYUSH therapies against COVID-19. Time-tested AYUSH medicines that have proven efficacy on respiratory diseases and have very little to zero side effects must be employed on COVID 19 patients. The Ministry of AYUSH has about 1.4 million registered practitioners and a staff of 80,000 people. This manpower must be used to create awareness about preventive and precautionary measures against the disease. It is also very important that efficacy data of allopathic, AYUSH treatments and combinations of both be collected for all if not a large number of treatments in India. There is a need to ensure proper scientific and evidence based investigation using all the arsenal available. Furthermore, as stated above, quarantine centres can be set up in AYUSH hospitals, universities and colleges. Registered practitioners and qualified students should be allowed to take care of patients after being given adequate information by doctors having experience of quarantine patient management as a pilot project. This will prepare the AYUSH team of doctors and medical students to take care of patients in case of a sudden surge in infections. It is also an opportunity to initiate some measures, which will benefit the AYUSH sector and Indian healthcare in the long term. One of the concerns of healthcare administrators and policy makers is the absence of clinical trial validation of AYUSH system of medicines. Since Indian systems of medicine follow a different disease management protocol (i.e., Nidanapanchaka), allopathic clinical trial protocol may not be desirable. Also, since they are time-tested, where there is no medicine in the allopathic system, as is the case in the present times, the effectiveness of AYUSH medicines as preventive medicine, if any, can be tried and documented in a scientific way, if the people of medicine are optimistic about it. Such randomized trials should be conducted in a controlled environment and with the approval of the concerned authorities. Second is to enhance research in these areas. Apart from health and education infrastructure, the Ministry of AYUSH has five world-class Central Research Councils. Currently there are 822 research projects, including 203 clinical research and 24 clinical trials being carried out by/under these councils. Specific research projects using AYUSH systems targeted at new pandemics like COVID-19 can be initiated under the aegis of these councils or universities. Third, India should also explore the possibility of developing international policy and programmes for the use of traditional medicine systems for appropriate interventions to manage and treat COVID-19 and similar pandemics. In this direction, the cooperation of other countries like China with strong traditional medicine systems can be sought. The relevant protocols will have to be approved by the World Health Organisation. This will require considerable diplomatic effort and documentation. The protocols that India develops in this area will come in handy. Fourth, this should be an opportunity for AYUSH systems to accept and use modern medical equipment, wherever appropriate, for diagnosis and treatment purposes. There is also a need for technical and scientific personnel with background in AYUSH systems doing research and development in this area. Technology cannot be ignored in the 21st century and if systems are to survive, they have to use it without losing the ethos of the systems. In any case, a large number of medical devices and diagnostic equipment like stethoscopes or blood pressure monitors are medical system neutral and many AYUSH practitioners are already using them. The AYUSH industry can also play a major role in this. Fifth, it is essential to ensure adequate supply of raw herbs and plants. Cultivation of medicinal plants has to be taken up on a priority basis to ensure uninterrupted supply of AYUSH medicines when the demand increases. For this, specific schemes have to be launched apart from existing schemes. This will also help in the revival of the Indian economy once the pandemic is over. It will be a means of effecting immediate transfer of wealth to rural areas. Sixth, to revive the AYUSH pharmaceutical industry, most of which is in the micro, small and medium sector, it would be necessary to create some common facilities like solvents, testing laboratories, etc.


Previous Post Next Post

Contact Form